16
September 2024
ProBiotix Health
plc
("ProBiotix" or the "Company"
or, together with its subsidiary, the "Group")
New Commercial Partnership in
Greece
ProBiotix Health plc (AQSE: PBX),
the life sciences business developing probiotics to support
cardiometabolic health, is pleased to announce a commercial
partnership with Greece based consumer brands specialist Eifron SA
("Eifron").
As part of the terms of the
agreement, Eifron will introduce YourBiotixBP tablets,
containing LPLDL®, under its existing probiotic consumer brand, with the
anticipated product launch expected to be in Q1 2025. Through this
strategic partnership, Eifron will expand its own portfolio by
including a product for cholesterol and blood pressure lowering
based on LPLDL®. The addition of other
products from the ProBiotix portfolio will be evaluated by the
parties on an ongoing basis.
ProBiotix Health has received a
purchase order from Eifron, with the first sales planned for Greece
and thereafter in selected regions in Europe.
Founded in 2011, Eifron specialises
in innovative healthcare solutions and holds a strong market
position, particularly in Greece where it is among the top five
brands in the country. Its core focus is addressing unmet medical
needs by developing and distributing advanced product solutions for
the health sector, with particularly close ties among pharmacies
and healthcare professionals. The current Eifron product portfolio
includes pharmaceuticals, supplements, and medical
devices.
Steen Andersen, CEO of ProBiotix, commented: "This exceptional opportunity
to work with a science driven market leader like Eifron represents
another significant milestone in our efforts to expand our reach
and broaden the availability of our innovative cardiometabolic
health product solutions in Europe.
"Eifron's reputation and expertise in the health sector and
their commitment to natural solutions makes them an ideal partner
for us."
Elias Kartasiadis, CEO of Eifron,
added: "We are thrilled to partner with ProBiotix
Health and bring their scientifically-backed products to our
markets. This partnership aligns perfectly with our mission to
provide our customers with effective and natural health
solutions.
"We
believe this collaboration will help us expand our reach and offer
differentiation and added value to the growing group of consumers
looking to improve their cardiometabolic health."
For
further information, please contact:
|
ProBiotix Health plc
|
https://probiotixhealth-ir.com/
|
|
Steen Andersen, Chief
Executive
|
Contact
via Walbrook below
|
|
|
|
|
Peterhouse Capital Limited (Aquis Corporate Adviser and
Broker) Mark Anwyl
|
Tel: 020
7220 9793
|
|
|
|
|
Walbrook PR
Ltd
Anna Dunphy
|
probiotix@walbrookpr.com
Mob: 07876 741 001
|
|
|
| |